Menu
Search
|

Menu

Close
X

Chimerix Inc CMRX.OQ (NASDAQ Stock Exchange Global Market)

1.99 USD
+0.02 (+1.02%)
As of Feb 15
chart
Previous Close 1.97
Open 2.00
Volume 68,356
3m Avg Volume 65,572
Today’s High 2.03
Today’s Low 1.99
52 Week High 5.93
52 Week Low 1.96
Shares Outstanding (mil) 47.05
Market Capitalization (mil) 244.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.14 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
4
FY16
6
EPS (USD)
FY18
-1.139
FY17
-1.511
FY16
-1.652
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.70
Price to Sales (TTM)
vs sector
55.67
6.29
Price to Book (MRQ)
vs sector
0.98
5.26
Price to Cash Flow (TTM)
vs sector
--
24.98
Total Debt to Equity (MRQ)
vs sector
0.00
16.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.38
Return on Investment (TTM)
vs sector
-24.14
14.45
Return on Equity (TTM)
vs sector
-24.17
15.96

EXECUTIVE LEADERSHIP

Martha Demski
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Timothy Trost
interim Chief Executive Officer, Chief Financial Officer, Senior Vice President, Secretary, Since 2019
Salary: $275,000.00
Bonus: $34,375.00
Michael Alrutz
interim Chief Executive Officer, Senior Vice President, General Counsel, Since 2019
Salary: --
Bonus: --
W. Garrett Nichols
interim Chief Executive Officer, Chief Medical Officer, Since 2019
Salary: $128,523.00
Bonus: $45,728.00
Roy Ware
Chief Manufacturing and Technology Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2505 Meridian Pkwy Ste 100
DURHAM   NC   27713-2288

Phone: +1919.8061074

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.

SPONSORED STORIES